Coloplast has finalised its first pivotal clinical study on Luja, a new intermittent male catheter, designed to reduce the risk of urinary tract infections...
CABA-201 data package and experience from prior autoimmune cell therapy INDs informed Phase 1/2 clinical trial design, including the initial dose to be eva...
Søren Tulstrup, President and CEO, Hansa Biopharma said, "This phase 2 study of imlifidase in GBS is an important next step in understanding the rol...
In a case study, a 54-year-old male patient with a spontaneous fracture and osteoporosis achieved an “almost complete recovery of osteoporosis”...
© 2025 Biopharma Boardroom. All Rights Reserved.
